Arena Pharmaceuticals Inc Quick Ratio (ARNA) starting from the fourth quarter 2021 to fourth quarter 2020, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Arena Pharmaceuticals Inc   (NASDAQ: ARNA)

Arena Pharmaceuticals Inc 's Quick Ratio

ARNA's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the fourth quarter 2021, Quick Ratio fell to 17.13 below Arena Pharmaceuticals Inc average.

Within Major Pharmaceutical Preparations industry 121 other companies have achieved higher Quick Ratio than Arena Pharmaceuticals Inc in fourth quarter 2021. While Quick Ratio total ranking in the fourth quarter 2021 has deteriorated compared to the prior quarter from 222 to 368.

Explain Quick Ratio?
How much Cash & cash equivalents ARNA´s has?
What are ARNA´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

ARNA Quick Ratio (Dec 31 2021)
Q4		 (Sep 30 2021)
Q3		 (Jun 30 2021)
Q2		 (Mar 31 2021)
Q1		 (Dec 31 2020)
Q4
Y / Y Current Liabilities Change -9.1 % 12.51 % 27.69 % -12.23 % -0.29 %
Y / Y Cash & cash equivalent Change -50.14 % -33.92 % -17.01 % 469.79 % 49.28 %
Quick Ratio MRQ 17.13 25.69 41.49 49.54 31.23
ARNA's Total Ranking # 368 # 222 # 38 # 56 # 80
Seq. Current Liabilities Change 6.98 % 28.27 % 6.54 % -37.82 % 32.42 %
Seq. Cash & cash equivalent Change -28.66 % -20.57 % -10.77 % -1.38 % -5.46 %



Quick Ratio fourth quarter 2021 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 122
Healthcare Sector # 183
Overall Market # 368


Quick Ratio Statistics
High Average Low
77.39 21.27 1.68
(Jun 30 2018)   (Sep 30 2016)




Financial Statements
Arena Pharmaceuticals Inc 's Current Liabilities $ 32 Millions Visit ARNA's Balance sheet
Arena Pharmaceuticals Inc 's Cash & cash equivalent $ 550 Millions Visit ARNA's Balance sheet
Source of ARNA's Sales Visit ARNA's Sales by Geography


Cumulative Arena Pharmaceuticals Inc 's Quick Ratio

ARNA's Quick Ratio for the trailling 12 Months

ARNA Quick Ratio

 (Dec 31 2021)
12 Months		 (Sep 30 2021)
12 Months		 (Jun 30 2021)
12 Months		 (Mar 31 2021)
12 Months		 (Dec 31 2020)
12 Months
Y / Y Current Liabilities TTM Growth 2.03 % 4.98 % 11.79 % 12.72 % 22.71 %
Y / Y Cash & cash equivalent TTM Growth -6.91 % 20.4 % 50.16 % 66.56 % -0 %
Quick Ratio TTM 31.44 35.53 40.32 44.27 34.47
Total Ranking TTM # 5212 # 48 # 4447 # 4289 # 21
Seq. Current Liabilities TTM Growth -2.9 % 3.11 % 4.96 % -2.9 % -0.1 %
Seq. Cash & cash equivalent TTM Growth -14.06 % -9.15 % -4.39 % 24.71 % 11.15 %

Quick ratio ranking by company, industry and sector >> Back to ARNA Financial Strength Comparisons >> Go to Compare ARNA Quick Ratio to its Competitors

On the trailing twelve months basis In spite of the year on year decrease in ARNA's Current Liabilities to $32.14 millions, cumulative Quick Ratio to 31.44 above the company average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 604 other companies have achieved higher Quick Ratio than Arena Pharmaceuticals Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the third quarter 2021 from 48 to 5212.

Explain Quick Ratio?
How much Cash & cash equivalents ARNA´s has?
What are ARNA´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 605
Healthcare Sector # 1182
Within the Market # 5212


trailing twelve months Quick Ratio Statistics
High Average Low
18.17 5.94 1.72
(Mar 31 2019)   (Mar 31 2017)




Companies with similar Quick Ratio in the quarter ending Dec 31 2021, within Major Pharmaceutical Preparations Industry Quick RatioDec 31 2021 MRQ Cash & cash equivalentDec 31 2021 MRQ Current Liabilities
Eqrx Inc   45.93 $ 1,678.542  Millions$ 36.544  Millions
Calliditas Therapeutics Ab  45.71 $ 955.507  Millions$ 20.903  Millions
Nuvation Bio Inc   45.22 $ 765.392  Millions$ 16.925  Millions
Zomedica Corp   44.92 $ 194.952  Millions$ 4.340  Millions
Cocrystal Pharma Inc   44.89 $ 58.755  Millions$ 1.309  Millions
Psyence Biomedical ltd   44.85 $ 1.135  Millions$ 0.025  Millions
Rani Therapeutics Holdings Inc   44.49 $ 117.453  Millions$ 2.640  Millions
Atossa Therapeutics Inc   43.66 $ 136.487  Millions$ 3.126  Millions
Entrada Therapeutics Inc   43.32 $ 291.064  Millions$ 6.719  Millions
Third Harmonic Bio Inc   42.75 $ 128.280  Millions$ 3.001  Millions
Xenon Pharmaceuticals Inc   38.53 $ 551.774  Millions$ 14.322  Millions
Anaptysbio Inc   37.56 $ 548.097  Millions$ 14.594  Millions
Biomea Fusion Inc   37.42 $ 173.516  Millions$ 4.637  Millions
Longeveron Inc   37.26 $ 2,036.262  Millions$ 54.655  Millions
Imago Biosciences Inc   36.98 $ 217.410  Millions$ 5.879  Millions
Essa Pharma inc   35.84 $ 189.199  Millions$ 5.280  Millions
Sensei Biotherapeutics Inc   35.07 $ 147.621  Millions$ 4.209  Millions
Innoviva Inc   34.70 $ 201.525  Millions$ 5.807  Millions
Nuvalent Inc   32.79 $ 288.111  Millions$ 8.787  Millions
Acrivon Therapeutics Inc   32.53 $ 99.603  Millions$ 3.062  Millions
Chemomab Therapeutics Ltd   32.34 $ 61.161  Millions$ 1.891  Millions
Olema Pharmaceuticals Inc   31.85 $ 287.250  Millions$ 9.019  Millions
Diamedica Therapeutics Inc   30.66 $ 45.225  Millions$ 1.475  Millions
Lantern Pharma Inc   30.40 $ 70.725  Millions$ 2.326  Millions
Pardes Biosciences Inc   29.97 $ 268.678  Millions$ 8.965  Millions
Aprea Therapeutics Inc   29.94 $ 53.076  Millions$ 1.773  Millions
Point Biopharma Global Inc   29.93 $ 238.816  Millions$ 7.980  Millions
Prf Technologies Ltd   29.17 $ 16.571  Millions$ 0.568  Millions
Day One Biopharmaceuticals Inc   29.02 $ 284.309  Millions$ 9.798  Millions
Zevra Therapeutics Inc   29.00 $ 112.346  Millions$ 3.874  Millions

Date modified: 2026-09-18T13:11:04+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.